Abstract
The development of new and novel clinical therapies depends on our ability to translate basic research findings into meaningful clinical applications. These "translational studies" are expensive and complex but necessary if we are to develop new treatments that prevent or treat heart, lung, and blood diseases. This study describes newly created programs at NHLBI (National Heart, Lung, and Blood Institute), which support academic research efforts to translate gene- and cell-based therapies into viable clinical applications.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
